Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech was founded in 2018 to discover, develop, and bring transformational cell therapies to cancer patients around the world. Legend Biotech has quickly grown from a small start-up to a leading global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing off-the-shelf cell therapies for oncological indications.

Legend Biotech's mission is to develop treatments that improve the lives of cancer patients by discovering, developing and delivering powerful, life-saving cell therapies.

Legend Biotech's vision is to be pioneers in the development of next-generation cell therapy treatments, with a commitment to innovation, science, and quality to make a meaningful difference in the lives of patients.

Legend Biotech has been recognized globally for its achievements, including the 2020 Frost & Sullivan Best Practices Award in Cell and Gene Therapy and the 2020 Cell and Gene Therapy Insights Innovation Award.